Brief: Eloxx Pharmaceuticals Announces First Patients Enrolled In Phase 2 Clinical Study Evaluating Elx-02 For The Treatment Of Alport Syndrome
25/01/2023 13:14
Jan 25 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES FIRST PATIENTS ENROLLED IN
PHASE
2 CLINICAL STUDY EVALUATING ELX-02 FOR THE TREATMENT OF ALPORT
SYNDROME
* ELOXX PHARMACEUTICALS INC - TOPLINE RESULTS EXPECTED IN
FIRST
HALF OF 2023
* ELOXX PHARMACEUTICALS INC - TRIAL SITES OPEN IN AUSTRALIA
AND
UNITED KINGDOM
Source text for Eikon: ID:nGNX6NZ9px
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome